Effectiveness, safety and acceptability of medical abortion at home versus in the clinic: a systematic review and meta-analysis in response to COVID-19

Katherine Gambir ¹, Camille Garnsey,¹ Kelly Ann Necastro,² Thoai D Ngo^{1,3}

To cite: Gambir K, Garnsey C, Necastro KA, *et al*. Effectiveness, safety and acceptability of medical abortion at home versus in the clinic: a systematic review and meta-analysis in response to COVID-19. *BMJ Global Health* 2020;**5**:e003934. doi:10.1136/bmjgh-2020-003934

Handling editor Seye Abimbola

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjgh-2020-003934>).

Received 9 September 2020
Revised 25 November 2020
Accepted 26 November 2020

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Poverty, Gender and Youth Program, Population Council, New York, New York, USA

²Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA

³The GIRL Center, Population Council, New York, New York, USA

Correspondence to
Katherine Gambir;
kgambir@gmail.com

ABSTRACT

Background Increased access to home-based medical abortion may offer women a convenient, safe and effective abortion method, reduce burdens on healthcare systems and support social distancing during the COVID-19 pandemic. Home-based medical abortion is defined as any abortion where mifepristone, misoprostol or both medications are taken at home.

Methods A systematic review and meta-analysis of randomised controlled trials (RCTs) and non-randomised studies (NRSs) were conducted. We searched databases from inception to 10 July 2019 and 14 June 2020. Successful abortion was the main outcome of interest. Eligible studies were RCTs and NRSs studies with a concurrent comparison group comparing home versus clinic-based medical abortion. Risk ratios (RRs) and their 95% CIs were calculated. Estimates were calculated using a random-effects model. We used the Grading of Recommendations Assessment, Development and Evaluation approach to assess risk of bias by outcome and to evaluate the overall quality of the evidence.

Results We identified 6277 potentially eligible published studies. Nineteen studies (3 RCTs and 16 NRSs) were included with 11 576 women seeking abortion up to 9 weeks gestation. Neither the RCTs nor the NRS found any difference between home-based and clinic-based administration of medical abortion in having a successful abortion (RR 0.99, 95% CI 0.98 to 1.01, $I^2=0\%$; RR 0.99, 95% CI 0.97 to 1.01, $I^2=52\%$, respectively). The certainty of the evidence for the 16 NRSs was downgraded from low to very low due to high risk of bias and publication bias. The certainty of the evidence for the three RCTs was downgraded from high to moderate by one level for high risk of bias.

Conclusion Home-based medical abortion is effective, safe and acceptable to women. This evidence should be used to expand women's abortion options and ensure access to abortion for women during COVID-19 and beyond.

PROSPERO registration number CRD42020183171.

INTRODUCTION

Of the estimated 55 million abortions that occur worldwide each year, 25 million (45%)

Key questions

What is already known?

- In 2011, Ngo *et al* reviewed evidence from nine non-randomised studies (NRSs) which suggested that there is no difference in the effectiveness or acceptability of home-based medical abortion compared to clinic-based medical abortion (OR 0.8, 95% CI 0.5 to 1.5, I^2 69.4%).
- Since 2011, the evidence on home-based medical abortion has grown, particularly with the publication of three randomised controlled trials (RCTs), but access to home-based medical abortion remains limited, and restrictions on travel and movement put in place due to COVID-19 has further complicated access to abortion worldwide.
- A recent Cochrane review from 16 NRSs and 2 RCTs found no difference in effectiveness between self-administered and provider-administered abortions (risk ratio 0.99, 95% CI 0.97 to 1.01); but this review did not analyse the location of the procedure and the quality of evidence was reported as moderate for the RCTs and very low for the NRSs.

What are the new findings?

- Home-based medical abortion is effective, safe and acceptable to women.
- There is no difference in the effectiveness or safety of medical abortion completed at home or in a clinic.
- Home-based medication abortion was highly acceptable to women, supporting existing evidence that women may prefer home administration to clinic-based care for reasons related to control and privacy, preferences that may be more pronounced due to concerns around spreading or contracting novel coronavirus disease 2019 (COVID-19).

are unsafe, with most unsafe abortions occurring in low-resource settings.¹ The expanded use of medical abortion worldwide, and particularly in low-resource settings, has been linked to increasing rates of safe abortion, and a decline in the morbidity and mortality associated with unsafe abortion,^{2–4} yet access to medication abortion continues

Key questions

What do the new findings imply?

- Home-based medical abortion may be an important strategy to offer women a convenient, safe and effective abortion method, reduce burdens on healthcare systems and support social distancing policies during the COVID-19 pandemic and beyond.
- Researchers, policy-makers and practitioners must continue to work to develop, evaluate and expand access to novel and innovative service delivery models such as telemedicine for medical abortion, pharmacist and community health worker provision of medical abortion and home-based medical abortion with hotline support.
- The update to the evidence comes at a time of global crisis, policy-makers should use the evidence presented in this review alongside national and international guidelines on medical abortion to expand home-based abortion care during and following the pandemic.

to be limited by numerous restrictions.^{5–9} Health systems worldwide have been burdened by the COVID-19 global pandemic^{10–12} and the necessary but drastic restrictions on movement that governments worldwide have instated in response to the pandemic further complicate access to abortion.

Expanding access to home-based abortion care is an important strategy for protecting abortion access while slowing the spread of coronavirus and reducing burdens on healthcare systems, especially in settings where capacity and workforces are already strained and limited. Home-based medical abortion may involve the pregnant person taking both mifepristone and misoprostol at home or misoprostol only at home after taking mifepristone at a clinic. Either way, the model requires fewer clinic visits, alleviating burdens on healthcare facilities and providers and limiting points of contact.^{7 13} In this review, women who took either medication at home were classified as belonging to the home-based group. That is, women who took mifepristone and misoprostol at home or took only misoprostol at home after taking mifepristone in the clinic were classified as home-based participants. However, none of the eligible studies compared women who took both mifepristone and misoprostol at home to participants who took both medications at the clinic.

This systematic review and meta-analysis aims to compare the effectiveness, safety, and acceptability of home-based medical abortion versus clinic-based irrespective of regimen for women of any age seeking abortion services in any setting. This is an update to a review conducted in 2011 by Ngo *et al*.¹⁴ and includes the most-up-to-date evidence for health officials and other public health decision makers across the globe to make evidence-informed decisions on home-based medical abortion guidelines during and following the pandemic. The recent Cochrane review from 16 non-randomised studies (NRSs) and two randomised controlled trials (RCTs) that compared the effectiveness between self-administered and provider-administered abortions (risk ratio (RR) 0.99, 95% CI 0.97 to 1.01) did not analyse

the location of the procedure. However, abortion policies and clinical guidance are very precise on who can provide the procedure and where it takes place; therefore, it is important to provide this level of evidence for policy makers and clinicians. Given the number of new studies that have been published in the past decade, the persistent restrictions on medical abortion, the need to expand people's choices, and the importance of access to home-based medical abortion in the context of the COVID-19 crisis, it is critically important to assess the most up to date evidence on home-based abortion and provide these data to health officials to formulate guidelines during and following the pandemic.

METHODS

Search strategy and selection criteria

We conducted a systematic review and meta-analysis that updates the home-based versus clinic-based systematic review by Ngo *et al*.¹⁴ The search strategy used in this review is an update to the search conducted in July 2019 by Gambir *et al* for a review of the comparative effectiveness, safety, and acceptability of self-administered vs provider administered medical abortion review.¹⁵ All published and unpublished RCTs and NRSs were eligible for inclusion if the review if they: (1) had a comparison between home-based versus clinic-based medical abortion; (2) compared the safety, or effectiveness, or both of women in both groups (3) assessed outcomes prospectively and (4) included a sample of women of reproductive ages (15–49) who were able to provide informed consent and were seeking an induced abortion in any clinical setting. Studies that compared home-based and clinic-based administration of medical abortion, irrespective of the drug regimens, routes of administration, doses used and person who administered the drug(s) were considered eligible. Studies were excluded if they recruited women with missed or incomplete abortions, or women who had experienced intrauterine fetal deaths.

We searched without language restrictions. We searched MEDLINE, Embase, CINAHL, LILACS, ClinicalTrials.gov, Google Scholar and PubMed from inception to 14 June 2020. We searched Cochrane Central Register of Controlled Trials, POPLINE and WHO ICTRP from inception to 10 July 2019 (update searches were not performed for these databases as they were not available at the time of the update). We also searched the websites of Marie Stopes International, Ipas, Gynuity Health Projects, Population Council and the International Consortium for Medical Abortion and hand-searched reference lists of relevant trials and systematic reviews returned in the electronic search. The full search strategy is available in online supplemental appendix 1.

Three reviewers (KG, KAN and CG) independently screened titles and abstracts returned by the search and retrieved full texts of all studies that were potentially eligible for inclusion. They independently examined all full-text articles for inclusion in the review using the

predetermined inclusion and exclusion criteria. Disagreements and concerns about eligibility were resolved by discussion. Two studies^{16 17} were translated from French to English.

The protocol for this review was published on 5 May 2020, DOI: <https://doi.org/10.7910/DVN/NPG1GK/E5XNMJ>¹⁸

Data analysis

Three independent reviewers (KG, KAN, CG) extracted data from eligible studies using a data abstraction form the review authors designed and piloted. Reviewers requested data from study authors via email as needed. The proportion of women with successful abortion is the primary outcome for the review. For all studies, successful abortion was defined as a complete uterine evacuation without the need for surgical intervention. In each study, successful abortion was determined by the healthcare provider during the follow-up visit. We also extracted data on study design (including details of treatments provided to the intervention and comparison groups), home-based participants and comparison groups recruited and analysed, population characteristics, duration and prevalence of side effects, acceptability of medication abortion, companionship during abortion and compliance with medication abortion protocol and follow-up.

The primary measure of effect assessed in this review is the RR of having a successful home-based medical abortion compared with having a successful clinic-based medical abortion, and the 95% CI of the RR. We calculated the RR of having a successful abortion using the number of women recruited for each study and an intention-to-treat approach. When intention-to-treat data were not available, we used a per protocol approach. We also present RRs and 95% CIs for variables related to complications and acceptability. We reported test statistics and narrative summaries for outcomes of side effects, companionship during home administration and compliance with medical abortion protocol.

Two review authors (KG and KAN) independently assessed eligible RCTs using Cochrane risk of bias tools for RCTs and NRSs using ROBINS-I tool to assess bias at the outcome level for our primary outcome of successful abortion.¹⁹ We used Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria to determine the overall quality of evidence.¹⁹ We downgraded the quality of evidence of RCTs from a starting rating of 'high certainty' by one level for serious concerns or by two levels for very serious concerns about risk of bias, inconsistency, indirectness, imprecision and publication bias. For NRSs, we used the same downgrade approach, but started with a baseline rating of 'low certainty' due to the lack of randomisation. Two review authors (KG and KAN) worked independently to rate the overall evidence quality (eg, high, moderate, low or very low) and disagreements were resolved by discussion.

We synthesised effectiveness in a meta-analysis using a random effects model to create RRs and their 95% CIs.

This model was selected a priori to incorporate the effect of trial heterogeneity among prospective studies from different settings.¹⁴ The meta-analysis was conducted using standard weighted (by SE of estimate) linear regression using RevMan Web.²⁰ We constructed forest plots showing the RRs and their 95% CI for the primary outcome of successful abortion. We analysed RCTs and NRSs separately when summarising the effect sizes of successful abortion, and for secondary outcomes. We performed statistical analysis using RevMan Web.²⁰

We examined statistical heterogeneity, especially when there was any variation in the direction of the effect. Statistical heterogeneity was assessed with χ^2 and I^2 statistics with a cut-off point of $p < 0.10$ to indicate statistical heterogeneity and we used the I^2 statistic to quantify heterogeneity. We did not find substantial heterogeneity in our meta-analysis, and therefore, we did not explore possible explanations in subgroup analysis.

We did not conduct a sensitivity analysis to assess the effect of the risk of bias of the studies included in the main effects analysis, because of the results of our risk of bias assessments.

Patient and public involvement

Given this is a systematic review of available global evidence, patients who participated in the studies presented were not involved in the review process.

RESULTS

We identified 2643 non-duplicate citations through database searching, assessed 41 full-text articles for eligibility and included 19 studies in the meta-analysis and systematic review (figure 1). The updated June 2020 search yielded one additional study Song 2018 retrieved from PubMed. No data from unpublished studies were identified. One included study collected data in two locations—Tunisia and Vietnam and each location is classified as a separate study and data is presented separately in our review. All included studies reported on our primary outcome of successful abortion. Three studies were RCTs, and included data from 1452 women.^{21–23} Sixteen studies were NRSs and included data from 10 124 women.^{16 17 24–36} Sixteen studies were conducted in low-to-middle resource settings (Bangladesh,^{25 26} India,^{28 30 34} Nepal,^{22 31} China,^{21 23} Vietnam,^{32 33 35} Tunisia,^{29 35} Nigeria,³⁶ Albania²⁷ and Turkey²⁴). Two studies were conducted in France, a high resource setting.^{16 17} Table 1 provides more details on study characteristics.

The mean age of study participants ranged from 24.3 years³⁶ to 32.2 years of age.³⁵ Participants' maximum gestational age was under 9 weeks for 14 studies,^{16 17 21 23 24 27–29 31–35} and up to and including 9 weeks for the other five studies.^{22 25 26 30 36} Statistically significant differences between participants in the home-based and clinic-based groups were reported on variables including primigravida, parity, age and gestational age in six studies.^{16 17 28–30 32} Two studies³⁵ did not compare

Figure 1 Study selection, RCTs and NRSs. RCTs, randomised controlled trials.

participant characteristics at baseline (online supplemental table 1).

All studies used a combination regimen that involved the administration of mifepristone and misoprostol. All studies reported that 200mg of oral mifepristone was administered by a provider in the clinic or hospital, and that 24–48 hours later 400–800 µg of misoprostol was self-administered by the woman at home (intervention group) or by a provider in a clinic (comparison group) orally, buccally, vaginally or sublingually. Thus, in all included

studies, at least one stage of the process was supervised by a provider and took place in a clinic. Specific details on the medication abortion regimens used in included studies are provided in online supplemental table 1.

Studies conducted follow-up with participants 10–20 days after mifepristone administration^{17 22 24–27 29–36} or after the completion of post-treatment menstruation.^{21 23} Evidence from NRSs that reported on compliance showed no significant differences in compliance with the medical abortion protocol between the two

Table 1 Study characteristics

Study	Location	Study type	No of women recruited (lost to follow-up)		Successful abortion RR (95% CI)
			Home based (H)	Clinic based (C)	
Akin <i>et al</i> 2004 ²⁴	Turkey	NRS	104 (4)	104 (3)	1.11 (0.98 to 1.25)
Alam <i>et al</i> 2013 ²⁵	Bangladesh	NRS	540 (20)	111 (2)	1.04 (.97 to 1.11)
Alam <i>et al</i> 2018 ²⁶	Bangladesh	NRS	1619 (2)	125 (4)	1.01 (0.97 to 1.04)
Bracken <i>et al</i> 2006 ²⁷	Albania	NRS	361 (5**)	48 (1)	0.99 (0.95 to 1.04)
Bracken 2010 ²⁸	India	NRS	530 (21)	69 (3)	0.96 (0.89 to 1.04)
Dagousset <i>et al</i> 2004 ¹⁷	France	NRS	120 (0)	289 (0)	0.96 (0.92 to 1.00)
Elul <i>et al</i> 2001 ³⁵	Vietnam	NRS	106 (8)	14 (0)	1.22 (.93 to 1.61)
Elul <i>et al</i> 2001 ³⁵	Tunisia	NRS	170 (4)	25 (0)	1.06 (0.91 to 1.23)
Hajri <i>et al</i> 2004 ²⁹	Tunisia	NRS	252 (9)	82 (0)	1.04 (0.98 to 1.11)
Iyengar <i>et al</i> 2016 ³⁰	India	NRS	342 (not reported)	389 (not reported)	1.00 (0.96 to 1.04)
Karki <i>et al</i> 2009 ³¹	Nepal	NRS	323 (31)	77 (2)	0.63 (0.30 to 1.34)
Li <i>et al</i> 2017 ²¹	China	RCT	372 (2)	372 (7)	0.99 (0.97 to 1.01)
Ngoc <i>et al</i> 2004 ³²	Vietnam	NRS	1380 (24)	174 (0)	0.50 (0.26 to 0.98)
Okonufua <i>et al</i> 2014 ³⁶	Nigeria	NRS	159 (52)	32 (7)	0.97 (0.92 to 1.02)
Provansal <i>et al</i> 2009 ¹⁶	France	NRS	143 (30)	162 (64)	0.91 (0.84 to 0.97)
Raghavan <i>et al</i> 2012 ³³	Vietnam	NRS	1933 (not reported)	366 (not reported)	1.02 (0.99 to 1.04)
Shrestha and Sedhai 2014 ²²	Nepal	RCT	94 (2)	94 (2)	1.02 (0.92 to 1.14)
Shuchita <i>et al</i> 2008 ³⁴	India	NRS	76 (1)	23(1)	0.99 (0.89 to 1.10)
Song <i>et al</i> 2018 ²³	China	RCT	283 (38)	250 (29)	0.99 (0.95 to 1.03)

** Represents disaggregated loss-to follow-up (follow-up among both clinic and home users)
NRS, non-randomised studies; RCTs, randomised controlled trials; RR, risk ratio.

groups. Three studies^{25 26 28} found that the average proportion of home-based participants who completed the medical abortion regimen perfectly was 98.3% (2642/2687), compared with 98.0% (295/301) of women in the provider-administered group. Similarly, four studies^{25 26 34 35} reported that only 1.1% (26/2339) of women in the home-based group reported not taking the misoprostol on time, compared with 1.9% (5/269) in the clinic-based group. In the home-based group, an average of 1.5% (41/2687) did not return to the clinic for follow-up, compared with 3.0% (9/301) of women in the clinic-based group.^{25 26 28} Data from 12 NRSs found that, on average, 77.3% (4377/5600) of home-based participants had companionship during their abortion.^{16 17 24–26 28 30–32 34–36}

Risk of bias

We assessed the risk of bias for our primary outcome of successful abortion using GRADE criteria. We graded the certainty of the evidence for the three RCTs to be moderate. We downgraded the certainty due to high risk of bias. The RCT^{21–23} were classified as unclear risk of bias (online supplemental table 2). We did not assess publication bias for the success of medical abortion for the RCTs given there are only three studies.

For the 16 NRSs (all prospective cohort studies), we graded the certainty of the evidence for the outcome of successful abortion to be very low. We downgraded the findings by one level from low certainty of evidence due to high risk of bias (online supplemental table 3). We rated all 16 prospective cohort studies at serious risk of

bias because we judged at least one ‘risk of bias’ domain to be at serious risk of bias. All studies had a serious risk of bias in the same domains: bias due to measurement of outcomes and bias due to confounding. There was bias in measurement of outcomes because they were measured by assessors aware of whether participants had administered misoprostol at home or at the clinic. There was a serious risk of bias due to confounding because the studies were not randomised, and we do not know whether gestational age (a known confounder) had an independent effect on the outcome. In addition to bias due to measurement of outcomes and bias due to confounding seen in the other studies, we classified Provansal *et al*¹⁶ and Okonufua *et al*³⁶ to have a serious risk of bias due to missing data because outcome data were not available for over 20% of the participants.

Successful abortion

Data collected from 11 576 participants in 3 RCTs and 16 NRSs were included in our main effect analysis that evaluated the comparative success of home-based and clinic-based administration of medical abortion among women seeking abortion. Among 1452 participants, the three RCTs^{21–23} found no difference between home-based and clinic-based administration of medical abortion in having a successful abortion (RR 0.99, 95% CI 0.98 to 1.01; figure 2). Of the home-based participants, 95.3% (705/740) had a successful abortion, compared with 95.8% (682/712) in the clinic-based group. Similarly, across 10 124 participants in 16 NRSs there was no evidence of a difference in successful abortion between

Figure 2 Forest plot: successful abortion, RCTs. M-H, Mantel-Haenszel; RCTs, randomised controlled trials.

home-based and clinic-based participants (RR 0.99, 95% CI 0.97 to 1.01; figure 3). Evidence from the NRSs indicates that 93.8% (7559/8062) of home-based participants had a successful abortion compared with 94.0% (1939/2062) of clinic participants. The rates of successful abortion in the NRSs ranged from 86.7% (124/143)¹⁶ to 97.2% (345/355)²⁷ in the home-based group, and from 78.6% (11/14)³⁵ to 100% (32/32)³⁶ among the clinic-based group.

The certainty of the evidence for successful abortion ranged from very low (NRSs) to moderate (RCTs). The certainty of the evidence for the 16 NRS was downgraded from low to very low due to high risk of bias and

publication bias. The certainty of the evidence for the three RCTs was downgraded from moderate by one level for high risk of bias.

We completed meta-analysis on 16 NRSs and 3 RCTs with dichotomous prescribing outcomes. For our meta-analysis on successful abortion, we did not detect serious heterogeneity ($I^2=52\%$ for 16 NRSs and $I^2=0\%$ for three RCTs). We did not assess the RCTs for heterogeneity because only three studies were included.

Side-Effects

Side effects were reported inconsistently across studies, either as dichotomous or continuous measures. We did

Figure 3 Forest plot: successful abortion, NRSs. Published data from Ngo 2011, unpublished data received from trialist, unpublished data received from Ngo 2011, unpublished data received from trialist, unpublished data received from trialist. M-H, Mantel-Haenszel; NRSs, non-randomised studies.

not run meta-analyses of continuous measures because an insufficient number of studies reported on these outcomes. Side effects analysed in this review included pain/cramps, vomiting, fever/chills, nausea and heavy bleeding. Table 2 provides data on the proportion of participants in each group who reported side effects, and the duration of side effects by group.

Analyses of dichotomous measures showed no significant difference in the occurrence of any side effects between home-based and clinic-based participants, and the reported duration of all side-effects were comparable between the two groups.

The average observed rate of pain/cramps among home-based women was 60.0% (389/648) in RCTs and 31.4% (163/519) in NRSs, compared with 59.0% (366/620) and 12.9% (50/386) of clinic-based participants in RCTs and NRSs, respectively.^{21 23 30 34 36} Among these studies,³⁰ reported on severe abdominal pain and Shrestha and Sedhai reported on acceptable cramping. The mean rate of vomiting was 5.4% (40/740) for home-based RCT participants, 28.5% (676/2366) for home-based NRS participants, 5.6% (40/712) for clinic-based RCT participants and 24.7% (70/283) for clinic-based NRS participants.^{21-23 25 26 34 36} An average of 25.5% (189/740) and 59.1% (1563/2645) of home-based participants in the RCTs and NRSs, respectively, reported nausea, compared with 24.7% (176/712) and 58.7% (182/310) of RCT and NRS clinic-based participants.^{21-23 25-27 34 36} No RCTs reported dichotomous measures of fever/chills. The average observed rate of fever/chills in NRSs was 37.6% (803/2136) among women in the home-based group, and 16.0% (81/507) among women in the clinic-based group.^{25 30 34 36} Similarly, only NRSs reported heavy bleeding dichotomously, and the average observed events of heavy bleeding in these studies was 22.0% (584/2656) among women in the home group, compared with 20.9% (129/616) in the provider-administered group.^{25 26 30 34 36}

Across all studies, only two NRSs reported complications requiring hospitalisation; three participants from the home-based administration group and no participants from the clinic-based administration group reported complications requiring hospitalisations.^{17 26} Analysis showed no statistically significant difference in having any complication requiring hospitalisation between the two groups (RR 1.58, 95% CI 0.08 to 29.81).

Acceptability

Most studies reported on at least one acceptability measure. All three RCTs only reported on whether participants were satisfied or highly satisfied with the treatment. Studies that reported only proportions or provided events with no denominator and did not include enough information for the study authors to calculate the denominator are excluded from analysis, but data on acceptability from these studies is included in table 3.

Medication abortion was highly acceptable to women in both the home-based and clinic-based groups. Ninety-four per cent (94.6%; 700/740) of participants from

RCTs and 90.8% (4775/5258) of participants from NRSs who had home-based medical abortions reported being satisfied or highly satisfied with the method, compared with 94.5% (673/712) of clinic-based RCT participants and 89.4% (1256/1405) of clinic-based NRS participants.^{16 17 21-23 25 26 28-32 34 36} Data from NRSs indicate that a higher proportion of participants in the home-based medical abortion group indicated that they would select the medical abortion method again compared with the clinic group; 83.5% (2137/2560), compared with 53.6% (512/955), though these differences were not significant.^{16 17 26 30 31 36} Approximately 93% (2369/2258) of home-based NRS participants indicated that they would select home use for future medical abortion, compared with 33.1% (345/1043) of NRS participants in the clinic-based group.^{16 17 25 30 32 36} Only 4.1% (95/2337) of NRS participants in the home-based group (n=2337) indicated they would select clinic use for future medical abortion, compared with 64.7% (415/641) of clinic-based NRS participants.^{25 30 32 36} An average of 87.22% (2231/2558) of home-based NRS participants would recommend the medical procedure to a friend for a future abortion compared with 52.67% (503/955) of NRS women in the clinic-based group.^{16 17 26 30 31 36}

Meta-analysis did not reveal a difference between the two groups in the level of satisfaction with the procedure (risk difference (RD) 0.01, 95% CI -0.03 to 0.05) probability of choosing the medical abortion method again (RD 0.02, 95% CI -0.04 to 0.09), or the probability of recommending the medical abortion procedure to a friend (RD 0.06, 95% CI -0.04 to 0.15). However, the meta-analysis did provide evidence of a significant difference between the two groups in the probability of selecting home-based abortion for future medical abortion between the groups (RD 0.50, 95% CI 0.32 to 0.67; $I^2=96\%$) and selecting clinic-based abortion for future medical abortion between these groups (RD -0.58, 95% CI -0.62 to -0.54). For both of these significant findings, participants were statistically more likely to select the same abortion location they had experienced in the study.

DISCUSSION

This systematic review and meta-analysis demonstrates that home-based medical abortion, as practiced in the included studies is effective, safe and acceptable to women. This review provides an important update to Ngo's 2011 review, incorporating ten new studies, including three RCTs, that provides a new body of evidence illustrating that there is no difference in the safety, effectiveness, and acceptability between home-based versus clinic-based medical abortion.¹⁴ This body of evidence comes at a time of global pandemic, when providing access to home-based administration of medical abortion is a key strategy to protect access to abortion, reduce the transmission of COVID-19, and alleviate overburdened healthcare facilities and providers.

Table 2 Occurrence and duration of side effects

Study	Side-effect											
	Nausea				Heavy bleeding*				Vomiting			
	Mean # of days (SD)	% who reported	H	C	Mean # of days (SD)	% who reported	H	C	Mean # of days (SD)	% who reported	H	C
Akin <i>et al</i> 2004 ²⁴	2.0 (2.8)	NR	NR	NR	2.1 (2.3)	1.7 (2.5)	NR	NR	0.8 (2.0)	0.4 (1.0)	NR	NR
Alam <i>et al</i> 2013 ²⁵	NR	33.8	49.5	NR	NR	NR	69.8	65.1	NR	NR	23.7	25.7
Alam <i>et al</i> 2018 ²⁶	NR	70.3	71.1	NR	NR	NR	0.02	0	NR	NR	29.4	23.1
Bracken <i>et al</i> 2006 ²⁷	1.1 (1.4)	62.4	66.7	1.9 (1.7)	2.0 (2.0)	NR	NR	NR	0.7 (1.2)	0.7 (1.1)	33.7	33.3
Iyengar <i>et al</i> 2016 ³⁰	NR	NR	NR	NR	NR	NR	7.2	3.6	NR	NR	NR	NR
Li <i>et al</i> 2017 ²¹	NR	17.3	16.8	NR	NR	NR	NR	NR	NR	NR	3.8	4.3
Ngoc <i>et al</i> 2004 ³²	1.5 (0.8*)	NR	NR	2.5	2.4	NR	NR	NR	0.6	0.2*	NR	NR
Okonofua <i>et al</i> 2014 ³⁶	0.4 (0.9)	24.0	36.7	3.3 (2.5)	3.1 (1.7)	86.4	90.0	0.4 (0.7)	0.2 (0.7)	0.2 (0.7)	29.2	13.3
Raghavan <i>et al</i> 2012 ³³	0.4 (0.9)	24	36.7	3.3 (2.5)	3.1 (1.7)	86.4	90	0.4 (0.7)	0.2 (0.7)	0.2 (0.7)	29.2	13.3
Shrestha <i>et al</i> 2014 ⁴²	NR	5.4	16.3	NR	NR	NR	NR	NR	NR	NR	5.4	6.5
Shuchita <i>et al</i> 2008 ³⁴	2.4 (2.0)	52.5	57.1	3.5 (2.6)	3.3 (1.9)	87.1	80.9	1.7 (1.1)	1.2 (0.4)	1.2 (0.4)	44.8	47.6
Song <i>et al</i> 2018 ²³	NR	42.8	39.6	NR	NR	NR	NR	NR	NR	NR	7.4	7.2

Provansal *et al* 2009,¹⁶ Karki *et al* 2009,³¹ Hajri *et al* 2004,²⁹ Elul *et al*³⁵, Dagousset *et al*¹⁷ 2004, Bracken *et al* 2010²⁸ did not report any data on side effects.

*P<0.05.

C, clinic; H, home; NA, not available; NR, not reported.

Table 3 Acceptability of home-based and clinic-based medical abortion in studies included in systematic review comparing home-based and clinic-based medical abortion

Study	Satisfied or highly satisfied with method (%)			Would choose method again (%)			Would select home use of miso for future medical abortion (%)			Would select clinic use for future medical abortion (%)			Would recommend method to a friend (%)		
	H	C	MD	H	C	MD	H	C	MD	H	C	MD	H	C	MD
Akin <i>et al</i> 2004 ²⁴	NR	NR	NR	NR	NR	NR	94.0	44.4	49.6	6.9	55.6	-48.7	NR	NR	NR
Alam <i>et al</i> 2013 ²⁵	92.1	93.6	-1.5	76.2	15.4	60.8	93.0	41.3	51.7	7.0	58.7	-51.7	76.8	16.1	60.7
Alam <i>et al</i> 2018 ²⁶	95.3	93.4	1.9	94.4	94.2	0.2	86.4	60.5	25.9	13.5	39.5	-26.0	97.2	94.2	3.0
Bracken <i>et al</i> 2006 ²⁷	90.6	90.3	0.3	NR	NR	NR	95.6	40.4	55.2	4.4	60.0	-55.6	NR	NR	NR
Bracken 2010 ²⁸	90.7	92.3	-1.6	NR	NR	NR	95.3	NR	NR	NR	67.1	NR	NR	NR	NR
Dagousset 2004 ¹⁷	98.5	72.2	26.3	77.5	59.5	18.0	78.5	21.0	57.8	NR	NR	NR	78.8	50.67	28.13
Elul 2001, Viet Nam ³⁵	91.0	87.0	4.0	NR	NR	NR	93.0	33.0	60.0	7.0	67.0	-60.0	NR	NR	NR
Elul 2001, Tunisia ³⁵	94.0	91.0	3.0	NR	NR	NR	96.0	69.0	27.0	5.0	31.0	-26.0	NR	NR	NR
Hajiri <i>et al</i> 2004 ²⁹	94.1	88.3	5.8	96.5	89.4*	7.1	NR	NR	NR	NR	NR	NR	97.2	92.5*	4.7
Iyengar <i>et al</i> 2016 ³⁰	95.2	96.7	-1.5	8.3	11.6	-3.3	81.9	20.4	61.5	9.7	68.1	-58.4	22.2	13.7	8.5
Karki <i>et al</i> 2009 ³¹	88.3	97.3	-9.0	90.7	93.2	-2.5	NR	NR	NR	NR	NR	NR	92.9	98.6	-5.7
Li <i>et al</i> 2017 ²¹	98.6	98.7	-0.1	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Ngoc <i>et al</i> 2004 ³²	83.6	91.4	-7.8	NR	NR	NR	96.1	38.5	57.6	2.0	61.5	-59.5	NR	NR	NR
Okonofua <i>et al</i> 2014 ³⁶	95.4	100	-4.6	96.1	100	-3.9	97.2	31.0	66.2	2.8	69	-66.2	98.7	100	-1.3
Provansal <i>et al</i> 2009 ¹⁶	98.0	92.9	5.1	91.1	79.6*	11.5	89.1	85.0	4.1	NR	NR	NR	89.1	85.0	4.1
Shrestha <i>et al</i> 2014 ²²	83.7	83.7	0.0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Shuchita <i>et al</i> 2008 ³⁴	80	82.6	-2.6	NR	NR	NR	88%	NR	NR	NR	63%	NR	NR	NR	NR
Song <i>et al</i> 2018 ²³	92.9	92.4	0.5	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

Raghavan *et al* 2012 did not report on any acceptability variable.

*p<0.05.

C, clinic; H, home; MD, mean difference; NR, not reported.;

Evidence from the 3 RCTs combined with findings from 16 NRSs show that the effectiveness of medical abortion was high (>90%) across studies and that there were no statistically significant differences in the proportion of successful abortion between women who administered their medical abortions at home compared with those who were administered medications at the clinic. The overall certainty of the evidence was moderate. However, this is in part due to the fact that the GRADE criteria is designed to evaluate RCTs whereas our review includes only three RCTs compared with 16 NRSs.

In all studies and in both groups, serious complications related to medical abortion were rare. Analyses showed no differences in the rates of complications requiring hospitalisations between home-based and clinic-based participants. Side effects related to medical abortion were more common, but evidence on the rates of side effects in both groups indicate that differences between the two groups were not statistically significant. Rates of side effects and complications were consistent with those expected by the WHO guidelines and corroborate findings from previous studies.^{14 15 37 38} Additionally, rates of compliance with the medical abortion protocol and follow-up were higher with women who administered at home; findings that should help assuage concerns about compliance and follow-up among those who administer misoprostol at home. Of note, the mifepristone-in-clinic-misoprostol-at-home regimen used by all participants, a regimen classified as home based in our study, has become common practice in some settings, and emerging evidence suggests that the entire mifepristone-misoprostol medical abortion regimen can also be safely and acceptably completed by women at home.^{39–41}

This review documents general satisfaction with home-based care and a high likelihood that home-based participants would select home administration for a future abortion medical abortion. These findings support existing evidence that women are satisfied with, and may prefer home-based care for reasons related to convenience, privacy, and access to a support person.⁴² Additionally, people's need or preference for home-based care may only increase in light of the COVID-19 pandemic as the cost and time associated with travelling to seek an abortion was a major barrier to abortion care worldwide prior to the outbreak, particularly in areas with legal although restricted access,⁴³ and the reduction of travel associated with home-based care is one documented reason that people may need or prefer this option.^{3 44}

This review has limitations and potential biases. The gestational age for participants from studies included in our review range from 35 to 63 days. Thus, the experiences of people seeking medical abortion beyond 9 weeks of gestation are not represented in this review; however, a recently published paper demonstrated that prospective studies of home-based medical abortion up to 84 days are feasible.⁴⁵ All studies in this review used a combined mifepristone and misoprostol drug regimen and results are therefore not applicable to scenarios where mifepristone

is unavailable, or where misoprostol is used in higher doses. Finally, all women included in the studies engaged with and had access to clinic services at some point in their abortion process, and thus results are not applicable to settings where people have no interaction with formal healthcare services. Future studies should compare mifepristone and misoprostol administration or misoprostol only at home to mifepristone in clinic. Future research should also explore the efficacy, safety, and acceptability of home administration of medical abortion among people with pregnancies beyond 9 weeks of gestation, among those utilising a misoprostol-alone regimen, and those self-managing their abortions without in-person provider supervision, including those accessing abortifacients online or through pharmacies. Finally, further research is needed on subgroups who face systematic barriers to abortion access and therefore are at an increased risk for unsafe abortion, including adolescents in the Global South, adolescents and widowed and divorced people in humanitarian contexts, and those living in settings with restrictive abortion laws.

The majority of the data presented in this review were from NRSs, and results are thus inherently prone to selection bias.⁴⁶ Women in these studies were able to choose between home-based and clinic based methods, and it is possible that, for example, women who were affected by stigma, concerned about concealing their abortion, or did not have a comfortable home environment would be more likely to select the clinic-based method.^{47 48} The ability of the participant to select a method is an important ethical attribute of studies on abortion given the ethical issues inherent in denying people their choice in method, but this study design does contribute to risk of bias. Our review is also limited by the fact that no studies blinded the outcome assessor, methods for determining successful abortion varied across studies, and only one study reported controlling for confounding factors, including gestational age. Future studies should blind the outcome assessor to reduce performance bias and analyses should control for gestational age, a known confounder.

CONCLUSION

The COVID-19 pandemic creates both the necessity and opportunity to innovate to meet people's essential sexual and reproductive needs. These innovations must be integrated into long-term service delivery and policy strategies to expand abortion service delivery options in the post-COVID era. It is imperative that researchers, policy-makers and practitioners continue to develop, evaluate and expand access to novel and innovative service delivery models such as telemedicine for medical abortion, pharmacist and community health worker provision of medical abortion, and self-management of medical abortion with hotline support.^{5 49–52} Policy-makers should consider the new body of evidence presented in this review alongside national and international guidelines on medical abortion

to update their clinical guidelines and policies that expand access to home-based abortion care.

Offering people at or below 9 weeks of gestation with access to all necessary information and support, and providing them with the option to return to the clinic to take misoprostol, or administer the drug at home will not only protect access to safe, time-sensitive abortion care, but will also reduce the number and cost of clinic visits, and relieve the strain on already overburdened health-care systems worldwide.

Twitter Katherine Gambir @KatherineGambir

Acknowledgements We thank the authors who provided responses to our questions about their studies. We also thank Mary Chu, Population Council librarian, for supporting us on the search strategy.

Contributors CG drafted the protocol with input from KG and TDN. KG developed and ran the search strategy. KG, KAN and CG obtained copies of the studies. KG, KAN and CG selected which studies to include. KG, KAN and CG extracted data from studies and entered data into RevMan Web Version. KG and KAN assessed risk of bias and certainty of evidence for the primary and secondary outcomes in each study. KG conducted the analysis with input from KAN, CG and TDN. CG interpreted the analysis and drafted the final review with support from KG and TDN.

Funding The systematic review and meta-analysis were supported by funding from the William & Flora Hewlett Foundation.

Disclaimer The findings and conclusions presented in this paper are those of the authors and do not necessarily reflect the official position of William & Flora Hewlett Foundation.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on request. We permit the sharing of data from this research article. All data published in this article are available on written request to authors.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

Author note We acknowledge that not all people who seek and receive abortion care identify as women. However, existing research on this topic specifically refers to women, and our review includes studies that only recruited women to participate. Thus, throughout this paper, we use the words 'woman/women' and the pronouns 'she/her' when discussing our data in the studies reviewed. We use the more gender-inclusive term 'people' in all other instances.

ORCID iD

Katherine Gambir <http://orcid.org/0000-0003-3491-0582>

REFERENCES

- Ganatra B, Gerdtz C, Rossier C, *et al*. Global, regional, and subregional classification of abortions by safety, 2010–14: estimates from a Bayesian hierarchical model. *The Lancet* 2017;390:2372–81.
- Singh S, Remez L, Sedgh G, *et al*. Abortion worldwide 2017: Uneven Progress and Unequal Access. N Y Guttmacher Inst.
- Berer M. Medical abortion: issues of choice and acceptability. *Reprod Health Matters* 2005;13:25–34.
- Barot S. The roadmap to safe abortion worldwide: lessons from new global trends on incidence, legality and safety. *N Y Guttmacher Inst* 2018;21:6.
- Footman K, Keenan K, Reiss K, *et al*. Medical abortion provision by pharmacies and drug sellers in low- and middle-income countries: a systematic review. *Stud Fam Plann* 2018;49:57–70.
- Yarnall J, Swica Y, Winikoff B. Non-Physician clinicians can safely provide first trimester medical abortion. *Reprod Health Matters* 2009;17:61–9.
- Guttmacher Institute. Medication abortion restrictions burden women and Providers—and threaten U.S. trend toward very early abortion, 2013. Available: <https://www.guttmacher.org/gpr/2013/03/medication-abortion-restrictions-burden-women-and-providers-and-threaten-us-trend-toward> [Accessed 14 Apr 2020].
- World Health Organization. *Safe abortion: technical and policy guidance for health systems evidence summaries and grade tables*. World Health Organization, 2012.
- Shannon C, Winikoff B. How much supervision is necessary for women taking mifepristone and misoprostol for early medical abortion? *Womens Health* 2008;4:107–11.
- World Health Organization (WHO). Shortage of personal protective equipment endangering health workers worldwide: who 2020.
- Schwartz M. Nurses die, doctors fall sick and panic rises on virus front lines. the new York times, 2020. Available: <https://www.nytimes.com/2020/03/30/nyregion/ny-coronavirus-doctors-sick.html> [Accessed 14 Apr 2020].
- Cavallo JJ, Donoho DA, Forman HP. Hospital capacity and operations in the coronavirus disease 2019 (COVID-19) Pandemic—Planning for the Nth patient. *American Medical Association* 2020:e200345.
- Ho PC. Women's perceptions on medical abortion. *Contraception* 2006;74:11–15.
- Ngo TD, Park MH, Shakur H, *et al*. Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review. *Bull World Health Organ* 2011;89:360–70.
- Gambir K, Kim C, Necastro KA, *et al*. Self-Administered versus provider-administered medical abortion. *Cochrane Database Syst Rev* 2020;3:CD013181.
- Provansal M, Mimari R, Grégoire B, *et al*. [Medical abortion at home and at hospital: a trial of efficacy and acceptability]. *Gynecol Obstet Fertil* 2009;37:850–6.
- Dagousset I, Fourrier E, Aubény E, *et al*. [Use of Misoprostol for medical abortion: a trial of the acceptability for home use]. *Gynecol Obstet Fertil* 2004;32:28–33.
- Gambir K, Garnsey C, Necastro KA, *et al*. Effectiveness, safety, and acceptability of medical abortion at home versus in the clinic: an updated systematic review in response to COVID-19 2020.
- BMJ Best Practice. What is grade? Available: <https://bestpractice.bmj.com/info/us/toolkit/learn-ebm/what-is-grade/> [Accessed 24 Apr 2020].
- The Cochrane Collaboration. Review manager web (RevMan web.). 2019.
- Li C-L, Song L-P, Tang S-Y, *et al*. Efficacy, safety, and acceptability of low-dose mifepristone and self-administered misoprostol for ultra-early medical abortion: a randomized controlled trial. *Reprod Sci* 2017;24:731–7.
- Shrestha A, Sedhai LB. A randomized trial of hospital vs home self administration of vaginal misoprostol for medical abortion. *Kathmandu Univ Med J* 2014;12:185–9.
- Song L-P, Tang S-Y, Li C-L, *et al*. Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol. *J Obstet Gynaecol Res* 2018;44:1705–11.
- Akin A, Blum J, Özalp S, *et al*. Results and lessons learned from a small medical abortion clinical study in turkey. *Contraception* 2004;70:401–6.
- Alam A, Bracken H, Johnston HB, *et al*. Acceptability and feasibility of mifepristone-misoprostol for menstrual regulation in Bangladesh. *Int Perspect Sex Reprod Health* 2013;39:79–87.
- Alam A, Lotarevich T, Das TR, *et al*. Mifepristone-misoprostol for menstrual regulation in public sector facilities in Bangladesh. *Int J Gynaecol Obstet* 2018;140:205–10.
- Bracken H, Gliozheni O, Kati K, *et al*. Mifepristone medical abortion in Albania: results from a pilot clinical research study. *Eur J Contracept Reprod Health Care* 2006;11:38–46.
- Bracken H. Family Planning Association of India (FPAI)/Gynuity Health Projects Research Group for Simplifying Medical Abortion in India. Home administration of misoprostol for early medical abortion in India. *Int J Gynecol Obstet* 2010;108:228–32.

- 29 Hajri S, Blum J, Gueddana N, *et al.* Expanding medical abortion in Tunisia: women's experiences from a multi-site expansion study. *Contraception* 2004;70:487–91.
- 30 Iyengar K, Klingberg-Alvin M, Iyengar SD, *et al.* Home use of misoprostol for early medical abortion in a low resource setting: secondary analysis of a randomized controlled trial. *Acta Obstet Gynecol Scand* 2016;95:173–81.
- 31 Karki C, Pokharel H, Kushwaha A, *et al.* Acceptability and feasibility of medical abortion in Nepal. *Int J Gynecol Obstet* 2009;106:39–42.
- 32 Ngoc NTN, Nhan VQ, Blum J, *et al.* Is home-based administration of prostaglandin safe and feasible for medical abortion? results from a multisite study in Vietnam. *BJOG Int J Obstet Gynaecol* 2004;111:814–9.
- 33 Raghavan S, Ngoc NthiN, Shochet T, *et al.* Clinic-level introduction of medical abortion in Vietnam. *Int J Gynaecol Obstet* 2012;119:39–43.
- 34 Shuchita M, Shveta K, Batya E, *et al.* Simplifying medical abortion: home administration of misoprostol. *J Obstet Gynecol India* 2008;58:410–6.
- 35 Elul B, Hajri S, Ellertson C, *et al.* Can women in less-developed countries use a simplified medical abortion regimen? *The Lancet* 2001;357:1402–5.
- 36 Okonofua F, Shittu O, Shochet T, *et al.* Acceptability and feasibility of medical abortion with mifepristone and misoprostol in Nigeria. *Int J Gynaecol Obstet* 2014;125:49–52.
- 37 WHO. Medical management of abortion. WHO. Available: <http://www.who.int/reproductivehealth/publications/medical-management-abortion/en/> [Accessed 14 Apr 2020].
- 38 Kruse B, Poppema S, Creinin MD, *et al.* Management of side effects and complications in medical abortion. *Am J Obstet Gynecol* 2000;183:S65–75.
- 39 Chong E, Frye LJ, Castle J, *et al.* A prospective, non-randomized study of home use of mifepristone for medical abortion in the U.S. *Contraception* 2015;92:215–9.
- 40 Louie KS, Tsereteli T, Chong E, *et al.* Acceptability and feasibility of mifepristone medical abortion in the early first trimester in Azerbaijan. *Eur J Contracept Reprod Health Care* 2014;19:457–64.
- 41 Platais I, Tsereteli T, Grebennikova G, *et al.* Prospective study of home use of mifepristone and misoprostol for medical abortion up to 10 weeks of pregnancy in Kazakhstan. *Int J Gynecol Obstet* 2016;134:268–71.
- 42 Moseson H, Herold S, Filippa S, *et al.* Self-managed abortion: a systematic scoping review. *Best Pract Res Clin Obstet Gynaecol* 2020;63:87–110.
- 43 Barr-Walker J, Jayaweera RT, Ramirez AM, *et al.* Experiences of women who travel for abortion: a mixed methods systematic review. *PLoS One* 2019;14:14.
- 44 Fuentes L, Baum S, Keefe-Oates B, *et al.* Texas women's decisions and experiences regarding self-managed abortion. *BMC Womens Health* 2020;20:6.
- 45 Moseson H, Jayaweera R, Raifman S, *et al.* Self-managed medication abortion outcomes: results from a prospective pilot study. *Reprod Health* 2020;17:1644 <https://doi.org/>
- 46 Reeves BC, Deeks JJ, Higgins J. 13 including non-randomized studies. *Cochrane Handb Syst Rev Interv* 2008;1:391.
- 47 Lohr PA, Wade J, Riley L, *et al.* Women's opinions on the home management of early medical abortion in the UK. *J Fam Plann Reprod Health Care* 2010;36:21–5.
- 48 Shellenberg KM, Moore AM, Bankole A, *et al.* Social stigma and disclosure about induced abortion: results from an exploratory study. *Glob Public Health* 2011;6:S111–25.
- 49 Grossman D, Grindlay K. Safety of medical abortion provided through telemedicine compared with in person. *Obstet Gynecol* 2017;130:778–82.
- 50 Gerdts C, Hudaya I. Quality of care in a safe-abortion Hotline in Indonesia: beyond harm reduction. *Am J Public Health* 2016;106:2071–5.
- 51 Drovetta RI. Safe abortion information hotlines: an effective strategy for increasing women's access to safe abortions in Latin America. *Reprod Health Matters* 2015;23:47–57.
- 52 Gerdts C, Jayaweera RT, Kristianingrum IA, *et al.* Effect of a smartphone intervention on self-managed medication abortion experiences among safe-abortion Hotline clients in Indonesia: a randomized controlled trial. *Int J Gynecol Obstet* 2020;149:48–55.